Umeclidinium bromide clinical trials
Also written Anoro Ellipta.
Counted the way a researcher would: Umeclidinium bromide with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How each study uses umeclidinium bromide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 18 Dec 2013 · ANORO ELLIPTA · NDA 203975 (FDA, Drugs@FDA; in a combination)
- European Union
- 28 Apr 2014 · Incruse Ellipta (previously Incruse) · EMEA/H/C/002809 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2013 (3)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2013 | 3 |
| 2014 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2021 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 3
GlaxoSmithKline (6) · Samsung Medical Center (1) · University of Virginia (1) · Queen's University (1)
Often tested with
Tested in the same studies.
Fluticasone (3) · Fluticasone furoate (2) · Vilanterol (2) · Vilanterol trifenatate (1) · GSK573719 (1)
Related medicines
As reviewed, each with the page that says it.
- One of Cholinergic Antagonists source
- One of Antimuscarinics source
Studies
Open first, then newest update. How each study uses umeclidinium bromide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled AsthmaActive, not recruitingPhase 4GlaxoSmithKlineNCT06372496Written as Fluticasone furoate/umeclidinium bromide/vilanterol trifenatate
- Effect of Perioperative Bronchodilator in COPD Patients Undergoing Lung Cancer SurgeryActive, not recruitingPhase 3Samsung Medical CenterNCT04536675Written as Vilanterol and Umeclidinium Bromide
- Hyperpolarized Xenon-129 MRI: a New Multi-dimensional Biomarker to Determine Pulmonary Physiologic Responses to COPD TherapeuticsActive, not recruitingPhase 2University of VirginiaNCT03002389Written as Anoro Ellipta
- A 24 Week Efficacy Study of Inhaled Umeclidinium (UMEC) in Patients of Chronic Obstructive Pulmonary Disease (COPD) Using a Novel Dry Powder Inhaler (NDPI)CompletedPhase 3GlaxoSmithKlineNCT02184611Written as Umeclidinium bromide
- A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 3GlaxoSmithKlineNCT02164513Written as umeclidinium bromide (UMEC)
- Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 WeeksCompletedPhase 3GlaxoSmithKlineNCT01772134Written as Umeclidinium bromide 62.5mcg
- A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD)CompletedPhase 3GlaxoSmithKlineNCT01822899Written as Umeclidinium bromide/Vilanterol
- Effect of a New Combination Bronchodilator on Exercise in GOLD Stage II Moderate COPDCompletedPhase 3Queen's UniversityNCT01491802Written as LAMA/LABA
- Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.CompletedPhase 3GlaxoSmithKlineNCT01772147Written as Umeclidinium bromide 62.5mcg
Given beside what is tested · 1 — umeclidinium bromide is usual care or a partner of the new treatment
As the comparator · 2 — what is tested is compared with umeclidinium bromide
- ANTES B+ Clinical TrialTerminatedPhase 4Fundacio Privada Mon Clinic BarcelonaNCT06282861Written as Incruse
- A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose in Healthy Volunteers, Repeat Doses in Asthmatic Patients and of Single Dose in COPD Patients of CHF6366CompletedPhase 1/2Chiesi Farmaceutici S.p.A.NCT03378648Written as umeclidinium bromide and vilanterol trifenatate
Codes
What other systems call umeclidinium bromide · ClinicalTrials.gg INT015447
- UNII (FDA) 7AN603V4JVUMECLIDINIUM BROMIDEConfirmed FDA, Wikidata
- RxNorm 1487512Confirmed FDA, Wikidata
- Wikidata Q15624035umeclidinium bromideConfirmed FDA, Wikidata
- NCI Thesaurus C152797Umeclidinium BromideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 7AN603V4JV | UMECLIDINIUM BROMIDE | Confirmed FDA, Wikidata |
| RxNorm | 1487512 | — | Confirmed FDA, Wikidata |
| Wikidata | Q15624035 | umeclidinium bromide | Confirmed FDA, Wikidata |
| NCI Thesaurus | C152797 | Umeclidinium Bromide | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.